Pulmonary Disorders and COVID-19: Difference between revisions
Jump to navigation
Jump to search
Sara Mohsin (talk | contribs) |
Sara Mohsin (talk | contribs) |
||
Line 19: | Line 19: | ||
===Respiratory failure=== | ===Respiratory failure=== | ||
===Increased mortality in COPD patients=== | |||
*According to a study conducted in China, having an underlying comorbidity such as chronic obstructive pulmonary disease (COPD) conferred a mortality hazard ratio of 2.681, even after adjusting for smoking status.<ref name="pmid32217650">{{cite journal| author=Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM | display-authors=etal| title=Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. | journal=Eur Respir J | year= 2020 | volume= 55 | issue= 5 | pages= | pmid=32217650 | doi=10.1183/13993003.00547-2020 | pmc=7098485 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32217650 }} </ref> | |||
==References== | ==References== |
Revision as of 15:40, 18 June 2020
To go to the COVID-19 project topics list, click here.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2]
Overview
Complications
Acute respiratory distress syndrome
Pneumonia
Pulmonary embolism
Hypoxemia
Superinfection
Respiratory failure
Increased mortality in COPD patients
- According to a study conducted in China, having an underlying comorbidity such as chronic obstructive pulmonary disease (COPD) conferred a mortality hazard ratio of 2.681, even after adjusting for smoking status.[1]
References
- ↑ Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM; et al. (2020). "Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis". Eur Respir J. 55 (5). doi:10.1183/13993003.00547-2020. PMC 7098485 Check
|pmc=
value (help). PMID 32217650 Check|pmid=
value (help).